topotecan.rTheoretical

▶ St John’s Wort decreases the efficacy of ulipristal. For FSRH

guidance, see

Anecdotal

Contraceptives, interactions p. 794.r

▶ St John’s Wort is predicted to decrease the exposure to

velpatasvir. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

venetoclax. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

vismodegib. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the concentration of

voxilaprevir. Avoid.rTheoretical

Statins → see TABLE 1 p. 1375 (hepatotoxicity)

atorvastatin . fluvastatin . pravastatin .rosuvastatin . simvastatin. ▶ Atorvastatin slightly to moderately increases the exposure to

aliskiren.oStudy

▶ Antacids moderately decrease the absorption of rosuvastatin.

Separate administration by 2 hours.oStudy

▶ Antiarrhythmics (amiodarone) are predicted to increase the risk

of rhabdomyolysis when given with atorvastatin. Monitor and

adjust dose.oTheoretical

▶ Antiarrhythmics (amiodarone) are predicted to increase the

exposure to fluvastatin.rTheoretical

▶ Antiarrhythmics (amiodarone) increase the risk of

rhabdomyolysis when given with simvastatin. Adjust

simvastatin dose, p. 205.rStudy

BNF 78 St John’s Wort — Statins 1533

Interactions | Appendix 1

A1

Statins (continued)

▶ Antiarrhythmics (dronedarone) are predicted to increase the

exposure to

Study

atorvastatin. Monitor and adjust dose.r

▶ Antiarrhythmics (dronedarone) slightly increase the exposure to

rosuvastatin. Adjust dose.rStudy

▶ Antiarrhythmics (dronedarone) are predicted to increase the

exposure to simvastatin. Use with caution and adjust

simvastatin dose, p. 205.rStudy

▶ Antiepileptics (carbamazepine) moderately decrease the

exposure to

Study → Also see

simvastatin

TABLE 1 p. 1375

. Monitor and adjust dose.r

▶ Antiepileptics (carbamazepine, eslicarbazepine) are predicted to

decrease the exposure to atorvastatin. Monitor and adjust

dose.oTheoretical → Also see TABLE 1 p. 1375

▶ Antiepileptics (eslicarbazepine) moderately decrease the

exposure to

Study

simvastatin. Monitor and adjust dose.o ▶ Antiepileptics (fosphenytoin, phenytoin) potentially decrease

the exposure to

Anecdotal

statins (atorvastatin, simvastatin).o ▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)

are predicted to increase the exposure to atorvastatin.

Monitor and adjust dose.rStudy → Also see TABLE 1 p. 1375

▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)

are predicted to increase the exposure to simvastatin. Use with

caution and adjust simvastatin dose, p. 205.rStudy → Also

see TABLE 1 p. 1375

▶ Antifungals, azoles (fluconazole, miconazole) are predicted to

increase the exposure to fluvastatin.rTheoretical → Also

see TABLE 1 p. 1375

▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are

predicted to increase the exposure to atorvastatin. Avoid or

adjust dose and monitor rhabdomyolysis.rStudy → Also

see TABLE 1 p. 1375

▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are

predicted to increase the exposure to

r

simvastatin. Avoid.

Study → Also see TABLE 1 p. 1375

▶ Antifungals, azoles (miconazole) potentially increase the

exposure to atorvastatin.rAnecdotal

▶ Antifungals, azoles (miconazole) are predicted to increase the

exposure to simvastatin. Avoid.rTheoretical

▶ Antifungals, azoles (isavuconazole) are predicted to increase the

exposure to

Theoretical

statins (fluvastatin, rosuvastatin).o ▶ Apalutamide slightly decreases the exposure to rosuvastatin.

nStudy

▶ Apalutamide is predicted to decrease the exposure to

simvastatin. Avoid or monitor.oStudy

▶ Aprepitant is predicted to increase the exposure to

atorvastatin. Monitor and adjust dose.rStudy

▶ Aprepitant is predicted to increase the exposure to

simvastatin. Use with caution and adjust simvastatin dose,

p. 205.rStudy

▶ Bosentan slightly decreases the exposure to atorvastatin.n

Study

▶ Bosentan

o

moderately decreases the exposure to simvastatin.

Study

▶ Calcium channel blockers (amlodipine) slightly increase the

exposure to simvastatin. Adjust simvastatin dose, p. 205.n

Study

▶ Calcium channel blockers (diltiazem, verapamil) are predicted to

increase the exposure to atorvastatin. Monitor and adjust

dose.rStudy

▶ Calcium channel blockers (diltiazem, verapamil) are predicted to

increase the exposure to simvastatin. Use with caution and

adjust simvastatin dose, p. 205.rStudy

▶ Cephalosporins (ceftobiprole) are predicted to increase the

concentration of statins.oTheoretical

▶ Ciclosporin very markedly increases the exposure to

atorvastatin

Study

. Avoid or adjust atorvastatin dose, p. 202.r

▶ Ciclosporin

r

moderately increases the exposure to fluvastatin.

Study

▶ Ciclosporin markedly to very markedly increases the exposure

to pravastatin. Adjust dose.rStudy

▶ Ciclosporin markedly increases the exposure to statins

(rosuvastatin, simvastatin). Avoid.rStudy

▶ Clopidogrel increases the exposure to rosuvastatin. Adjust

rosuvastatin dose, p. 204.oStudy

▶ Cobicistat is predicted to increase the exposure to atorvastatin.

Avoid or adjust dose and monitor rhabdomyolysis.

Study

r

▶ Cobicistat is predicted to increase the exposure to simvastatin.

Avoid.rStudy

▶ Colchicine increases the risk of rhabdomyolysis when given

with statins.rAnecdotal

▶ Statins (fluvastatin, rosuvastatin) increase the anticoagulant

effect of coumarins. Monitor INR and adjust dose.rStudy

▶ Crizotinib is predicted to increase the exposure to atorvastatin.

Monitor and adjust dose.rStudy

▶ Crizotinib is predicted to increase the exposure to simvastatin.

Use with caution and adjust

Study

simvastatin dose, p. 205.r

▶ Danazol is predicted to increase the risk of rhabdomyolysis

when given with atorvastatin.rTheoretical

▶ Danazol increases the risk of rhabdomyolysis when given with

simvastatin. Avoid.rAnecdotal

▶ Statins are predicted to increase the risk of rhabdomyolysis

when given with daptomycin.rTheoretical

▶ Dasabuvir increases the exposure to rosuvastatin. Adjust

rosuvastatin dose, p. 204.oStudy

▶ Dasatinib

o

is predicted to increase the exposure to simvastatin.

Theoretical

▶ Efavirenz slightly decreases the exposure to atorvastatin.n

Study

▶ Efavirenz

o

moderately decreases the exposure to simvastatin.

Study

▶ Elbasvir increases the exposure to atorvastatin. Adjust

atorvastatin dose, p. 202.oStudy

▶ Elbasvir is predicted to increase the exposure to fluvastatin.

Adjust fluvastatin dose, p. 203.qTheoretical

▶ Elbasvir increases the exposure to rosuvastatin. Adjust

rosuvastatin dose, p. 204.oStudy

▶ Elbasvir is predicted to increase the exposure to simvastatin.

Adjust simvastatin dose, p. 205.qTheoretical

▶ Eltrombopag is predicted to increase the exposure to statins.

Monitor and adjust dose.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

simvastatin.rStudy

▶ Ezetimibe potentially increases the risk of rhabdomyolysis

when given with statins.rAnecdotal

▶ Fibrates (bezafibrate, ciprofibrate) increase the risk of

rhabdomyolysis when given with

Study

pravastatin. Avoid.r

▶ Fibrates (bezafibrate, ciprofibrate) increase the risk of

rhabdomyolysis when given with rosuvastatin. Adjust

rosuvastatin dose, p. 204.rStudy

▶ Fibrates (bezafibrate, ciprofibrate) increase the risk of

rhabdomyolysis when given with simvastatin. Adjust

simvastatin dose, p. 205.rStudy

▶ Fibrates (ciprofibrate) increase the risk of rhabdomyolysis

when given with

Study

atorvastatin. Avoid or adjust dose.r

▶ Fibrates (ciprofibrate) increase the risk of rhabdomyolysis

when given with fluvastatin.rStudy

▶ Fibrates (fenofibrate) are predicted to increase the risk of

rhabdomyolysis when given with fluvastatin. Adjust

fenofibrate dose, p. 199.rTheoretical

▶ Fibrates (fenofibrate) are predicted to increase the risk of

rhabdomyolysis when given with

Theoretical

pravastatin. Avoid.r

▶ Fibrates (fenofibrate) increase the risk of rhabdomyolysis when

given with rosuvastatin. Adjust fenofibrate and rosuvastatin

doses, p. 199, p. 204.rAnecdotal

▶ Fibrates (gemfibrozil) increase the risk of rhabdomyolysis when

given with statins. Avoid.rAnecdotal

▶ Fibrates (bezafibrate) increase the risk of rhabdomyolysis when

given with statins (atorvastatin, fluvastatin).rStudy

1534 Statins — Statins BNF 78

Interactions | Appendix 1

A1

▶ Fibrates (fenofibrate) increase the risk of rhabdomyolysis when

given with statins (atorvastatin, simvastatin). Adjust

fenofibrate dose, p. 199.rAnecdotal

▶ Fusidic acid increases the risk of rhabdomyolysis when given

with statins. Avoid.rAnecdotal

▶ Glecaprevir (with pibrentasvir) markedly increases the

exposure to atorvastatin. Avoid.rStudy

▶ Glecaprevir (with pibrentasvir) is predicted to increase the

exposure to fluvastatin.oTheoretical

▶ Glecaprevir (with pibrentasvir) increases the exposure to

pravastatin. Use with caution and adjust pravastatin dose,

p. 203.oStudy

▶ Glecaprevir (with pibrentasvir) increases the exposure to

rosuvastatin. Use with caution and adjust rosuvastatin dose,

p. 204.oStudy

▶ Glecaprevir (with pibrentasvir) increases the exposure to

simvastatin. Avoid.oStudy

▶ Grapefruit juice increases the exposure to atorvastatin.n

Study

▶ Grapefruit juice

r

increases the exposure to simvastatin. Avoid.

Study

▶ Grazoprevir increases the exposure to atorvastatin. Adjust

atorvastatin dose, p. 202.oStudy

▶ Grazoprevir is predicted to increase the exposure to

fluvastatin. Adjust fluvastatin dose, p. 203.qTheoretical

▶ Grazoprevir increases the exposure to rosuvastatin. Adjust

rosuvastatin dose, p. 204.oStudy

▶ Grazoprevir is predicted to increase the exposure to

simvastatin. Adjust simvastatin dose, p. 205.qTheoretical

▶ HIV-protease inhibitors are predicted to increase the exposure

to atorvastatin. Avoid or adjust dose and monitor

rhabdomyolysis.rStudy

▶ HIV-protease inhibitors slightly to moderately increase the

exposure to rosuvastatin. Avoid or adjust dose.rStudy

▶ HIV-protease inhibitors are predicted to increase the exposure

to simvastatin. Avoid.rStudy

▶ Idelalisib is predicted to increase the exposure to atorvastatin.

Avoid or adjust dose and monitor rhabdomyolysis.

Study

r

▶ Idelalisib is predicted to increase the exposure to simvastatin.

Avoid.rStudy

▶ Imatinib is predicted to increase the exposure to atorvastatin.

Monitor and adjust dose.rStudy

▶ Imatinib is predicted to increase the exposure to simvastatin.

Use with caution and adjust

Study

simvastatin dose, p. 205.r

▶ Ledipasvir is predicted to increase the exposure to

rosuvastatin. Avoid.rTheoretical

▶ Ledipasvir is predicted to increase the exposure to statins

(atorvastatin, fluvastatin, pravastatin, simvastatin). Monitor

and adjust dose.oTheoretical

▶ Leflunomide is predicted to increase the exposure to

rosuvastatin. Adjust dose.oStudy → Also see TABLE 1

p. 1375

▶ Leflunomide is predicted to increase the exposure to statins

(atorvastatin, fluvastatin, pravastatin, simvastatin)

Study → Also see TABLE 1 p. 1375

.o ▶ Letermovir moderately increases the exposure to atorvastatin.

Avoid or adjust atorvastatin dose, p. 202.rStudy

▶ Letermovir is predicted to increase the exposure to fluvastatin.

Monitor and adjust dose.oTheoretical

▶ Letermovir is predicted to increase the exposure to

pravastatin. Avoid or adjust dose.oTheoretical

▶ Letermovir is predicted to increase the exposure to statins

(rosuvastatin, simvastatin). Avoid.rStudy

▶ Lomitapide increases the exposure to atorvastatin. Adjust

lomitapide dose or separate administration by 12 hours, p. 207.

nStudy → Also see TABLE 1 p. 1375

▶ Lomitapide increases the exposure to simvastatin. Monitor and

adjust simvastatin dose, p. 205.oStudy → Also see TABLE 1

p. 1375

▶ Macrolides (clarithromycin) are predicted to increase the

exposure to atorvastatin. Avoid or adjust dose and monitor

rhabdomyolysis.rStudy

▶ Macrolides (clarithromycin) moderately increase the exposure

to pravastatin.rStudy

▶ Macrolides (clarithromycin) are predicted to increase the

exposure to simvastatin. Avoid.rStudy

▶ Macrolides (erythromycin) are predicted to increase the

exposure to

Study

atorvastatin. Monitor and adjust dose.r

▶ Macrolides (erythromycin) are predicted to increase the

exposure to pravastatin.rStudy

▶ Macrolides (erythromycin) are predicted to increase the

exposure to simvastatin. Use with caution and adjust

simvastatin dose, p. 205.rStudy

▶ Mitotane

r

is predicted to decrease the exposure to simvastatin.

Study

▶ Monoclonal antibodies (sarilumab) are predicted to decrease the

exposure to statins (atorvastatin, simvastatin).oStudy

▶ Monoclonal antibodies (tocilizumab) are predicted to decrease

the exposure to statins (atorvastatin, simvastatin). Monitor and

adjust dose.oStudy

▶ Netupitant is predicted to increase the exposure to

atorvastatin. Monitor and adjust dose.rStudy

▶ Netupitant is predicted to increase the exposure to

simvastatin. Use with caution and adjust simvastatin dose,

p. 205.rStudy

▶ Nevirapine slightly decreases the exposure to atorvastatin.

nStudy

▶ Nevirapine

o

moderately decreases the exposure to simvastatin.

Study

▶ Nicotinic acid is predicted to increase the risk of

rhabdomyolysis when given with statins.rTheoretical

▶ Nilotinib is predicted to increase the exposure to atorvastatin.

Monitor and adjust dose.rStudy

▶ Nilotinib is predicted to increase the exposure to simvastatin.

Use with caution and adjust

Study

simvastatin dose, p. 205.r

▶ Osimertinib

o

slightly increases the exposure to rosuvastatin.

Study

▶ Paritaprevir (in fixed-dose combination) is predicted to

increase the risk of rhabdomyolysis when given with

atorvastatin. Avoid.rTheoretical

▶ Paritaprevir (with ritonavir and ombitasvir) is predicted to

increase the exposure to

Theoretical

fluvastatin. Avoid.o ▶ Paritaprevir (with ritonavir and ombitasvir) increases the

exposure to

o

pravastatin. Adjust pravastatin dose, p. 203.

Study

▶ Paritaprevir (with ritonavir and ombitasvir) slightly to

moderately increases the exposure to rosuvastatin. Adjust

rosuvastatin dose, p. 204.oStudy

▶ Paritaprevir (in fixed-dose combination) is predicted to

increase the risk of rhabdomyolysis when given with

simvastatin. Avoid.rTheoretical

▶ Pazopanib

o

Comments

Search This Blog

Archive

Show more

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

علاقة البيبي بالفراولة بالالفا فيتو بروتين

التغيرات الخمس التي تحدث للجسم عند المشي

إحصائيات سنة 2020 | تعداد سكَان دول إفريقيا تنازليا :

ما هو الليمونير للأسنان ؟

ACUPAN 20 MG, Solution injectable

CELEPHI 200 MG, Gélule

الام الظهر

VOXCIB 200 MG, Gélule

ميبستان

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

Kana Brax Laberax

TRIPASS XR تري باس

PARANTAL 100 MG, Suppositoire بارانتال 100 مجم تحاميل

الكبد الدهني Fatty Liver

الم اسفل الظهر (الحاد) الذي يظهر بشكل مفاجئ bal-agrisi

SEDALGIC 37.5 MG / 325 MG, Comprimé pelliculé [P] سيدالجيك 37.5 مجم / 325 مجم ، قرص مغلف [P]

نمـو الدمـاغ والتطـور العقـلي لـدى الطفـل

CELEPHI 200 MG, Gélule

أخطر أنواع المخدرات فى العالم و الشرق الاوسط

Archive

Show more